Antiplatelet Drugs Market, by Drug Class (Irreversible Cyclooxygenase (COX) Inhibitors, Adenosine Diphosphate (ADP) Receptor Inhibitors, Glycoprotein IIB/IIIA Inhibitors, Adenosine Reuptake Inhibitors, and Thromboxane Inhibitors and Phosphodiesterase Inhibitors), by Mode of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Myocardial Infarction, Percutaneous Coronary Interventions, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Trends, and Forecast to 2026
- Report code : CMI62190 |
- Industry :
Pharmaceutical
- Published On : Oct 2018 |
- Pages : 185 Pages |
- Format :
Antiplatelet Drugs Market – Insights
Antiplatelet drugs are prescribed to individuals with a history of heart attacks and these drugs aid in reducing reoccurrence of heart attacks. Some of the antiplatelet medications include, aspirin, clopidogrel, prasugrel, and ticagrelor. Aspirin is recommended for all patients with Acute Coronary Syndrome (ACS), in the absence of hypersensitivity. It is prescribed along with one of the oral antiplatelet agents including Clopidogrel, Prasugrel, and Ticagrelor. Prasugrel is prescribed for patients suffering from ACS and for those undergoing Percutaneous Coronary Intervention (PCI). Clopidogrel and Ticagrelor aid in preventing atherothrombotic events in adult patients with ACS, and those who are treated with Coronary Artery Bypass Grafting (CABG) or PCI.
The global antiplatelet drugs market size was valued at US$ 1.5 billion in 2017 and is expected to witness a CAGR of 7.6% over the forecast period (2018 – 2026).
Global Antiplatelet Drugs Market Value (US$ Bn) & Y-o-Y Growth (%)
Source: Coherent Market Insights Analysis (2018)
Increasing incidence of cardiovascular diseases is expected to drive growth of the antiplatelet drugs market
Increasing prevalence of cardiovascular disorders, growing geriatric population, and sedentary lifestyle are some of the major factors driving the global antiplatelet drugs market growth. Cardiovascular diseases are the principal cause of death in the developed and emerging economies. According to a report by Centers for Disease Control and Prevention (CDC), 2015, around 800,000 people in the U.S. die annually due to stroke and other cardiovascular diseases. Some of the common cardiovascular diseases include, rheumatic heart disease, hypertensive heart disease, inflammatory heart disease, ischemic heart disease, and cerebrovascular heart disease.
Antiplatelet Drugs Market Restraints
However, limitations in efficacy, safety, and tolerability of some antiplatelet drugs have precluded their use in patients. For instance, antiplatelet drugs can irritate lining of the stomach that leads to gastrointestinal side effects such as indigestion and stomach aches. Moreover, patients using these drugs can be more prone to nosebleeds, bruising or bleeding for longer than usual since they reduce the ability of the blood to clot. According to the Journal of Clinical Gastroenterology 2011 report, most spontaneous bleeding in patients treated with antiplatelet drugs occurs in the gastrointestinal tract, with an incidence of 2-3% with dual antiplatelet therapy. Moreover, failure to take antiplatelet drugs as prescribed can possess increased risk of thrombotic complications, owing to rebound platelet activation. All these factors are expected to hinder growth of the antiplatelet drugs market during the forecast period.
Antiplatelet Drugs Market - Regional Insights
On the basis of region, the global antiplatelet drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America and Europe antiplatelet drugs market are expected to foresee significant growth by 2026 as cardiovascular diseases are the principal cause of death in these regions. According to a European Heart Journal 2014 study, Coronary Heart Diseases (CHD), particularly Myocardial Infarction (MI), is responsible for around 1.8 million deaths in Europe, annually.
Increasing prevalence of cardiovascular diseases in Asia Pacific is expected to fuel the antiplatelet market growth in the region. According to the American Heart Association, in 2011, 17,050 deaths among Asian and Pacific Islanders were due to cardiovascular diseases; 7,828 due to coronary heart disease; and 2,476 due to myocardial infarction.
However, according to the American Heart Journal 2015 data, people in Asia Pacific are susceptible to antithrombotics or fibrinolytics and to be associated with a higher bleeding risk during management of ischemic heart diseases and antithrombotic therapy. For instance, excessive bleeding risk with standard doses of new P2Y12 inhibitors is observed in patients in Asia Pacific, especially in its eastern region. According to the Circulation Journal 2014 report, for Prasugrel, a lower maintenance dose of 3.75 mg daily was used in clinical studies and approved for Japanese patients. The lower body weight of patients in Asia Pacific, fixed dose regimen of most antiplatelet drugs, and different genetic backgrounds are the potential factors responsible for increased risk of bleeding. Therefore, bleeding is viewed as a primary concern for selecting antiplatelet drugs for patients in Asia Pacific.
Global Antiplatelet Drugs Market Share 2017 (%), By Region
Source: Coherent Market Insights Analysis (2018)
Antiplatelet Drugs Market - Competitive Landscape
Key players operating in the global antiplatelet drugs market include, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company. Manufactures in the antiplatelet drugs market are focused on targeting either surface receptors or enzymes in the platelet in order to protect against unwanted clot formation following initial platelet activation.
Antiplatelet drugs are most effective for arterial clots that are made largely of platelets. These drugs prevent platelets from clumping and avoid clot formation. To achieve this effect, several of these medications act on receptors and proteins that receive chemical signals and cause cells to bind. Antiplatelet drugs are used as a first-line antithrombotic therapy for the management of acute ischemic syndromes and prevent their recurrence. For instance, aspirin blocks a blood-clotting chemical called thromboxane. The drug is sold under various brand names, such as Ecotrin, Aspir, Bayer, and Easprin. Aspirin is often prescribed to people experiencing a heart attack as the drug can effectively and rapidly inhibit platelet activity and growth of blood clot, thereby maintaining some measure of blood flow.
Market Dynamics
Increasing incidence of chronic diseases such as obesity, diabetes, and cardiovascular diseases (CVDs) is increasing the risk of heart attacks, which in turn is propelling demand for antiplatelet drugs. According to a report American Diabetes Association, in 2015, around 30.3 million people in the U.S suffered from diabetes, which was 9.4% of the country’s total population. According to a report by American Heart Association (AHA), in 2013, cardiovascular diseases accounted for over 17.3 million deaths worldwide, representing 31% of all deaths. According to the same source, CVDs are projected to affect 23.6 million people by 2030.
Moreover, increasing geriatric population, which is associated with high susceptibility to chronic diseases related to cardiac disorders is expected to boost growth of the global antiplatelet drugs market. According to the American Heart Association 2016 data, an estimated 85.6 million American adults suffer from 1 or more types of cardiovascular disease and 43.7 million of these are estimated to be 60 years or more.
However, side effects associated with antiplatelet drugs including bleeding is expected to adversely impact antiplatelet drugs market growth during the forecast period. Unforeseen incidences of increased bleeding risk and recurrent arterial thrombosis observed in patients have hampered the development of superior next generation antiplatelet therapies.
Key features of the study:
- This report provides in-depth analysis of the global antiplatelet drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global antiplatelet drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include, AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global antiplatelet drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for antiplatelet drugs market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Antiplatelet Drugs Market, By Drug Class:
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- Global Antiplatelet Drugs Market, By Mode of Administration:
- Oral
- Intravenous
- Global Antiplatelet Drugs Market, By Application:
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
- Global Antiplatelet Drugs Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Drug Class:
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- By Mode of Administration:
- Oral
- Intravenous
- By Application:
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Drug Class:
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- By Mode of Administration:
- Oral
- Intravenous
- By Application:
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Drug Class:
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- By Mode of Administration:
- Oral
- Intravenous
- By Application:
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Class:
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- By Mode of Administration:
- Oral
- Intravenous
- By Application:
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug Class:
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- By Mode of Administration:
- Oral
- Intravenous
- By Application:
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
- Africa
- By Country:
- South Africa
- Central Africa
- North Africa
- By Drug Class:
- Irreversible Cyclooxygenase (COX) Inhibitors
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Glycoprotein IIB/IIIA Inhibitors
- Adenosine Reuptake Inhibitors
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- By Mode of Administration:
- Oral
- Intravenous
- By Application:
- Angioplasty
- Arterial Thrombosis
- Myocardial Infarction
- Percutaneous Coronary Interventions
- Others
- Company Profiles
- AstraZeneca Plc*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo, Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Otsuka Pharmaceutical Company, Ltd.
- Sanofi
- The Medicines Company
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Mode of Administration
- Market Snippet, By Application
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Major Brand Analysis
- Pricing Analysis
- Reimbursement Scenario
- Epidemiology Analysis
- PORTER’S Five Forces
- Global Antiplatelet Drugs Market, By Drug Class, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Irreversible Cyclooxygenase (COX) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Adenosine Diphosphate (ADP) Receptor Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Glycoprotein IIB/IIIA Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Adenosine Reuptake Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Thromboxane Inhibitors and Phosphodiesterase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Global Antiplatelet Drugs Market, By Mode of Administration, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Global Antiplatelet Drugs Market, By Application, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Angioplasty
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Arterial Thrombosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Myocardial Infarction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Percutaneous Coronary Interventions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
- Global Antiplatelet Drugs Market, By Region, 2018 – 2026, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, By Region, 2016 – 2026
- Regional Trends
- North America
- Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Mode of Administration, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Mode of Administration, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Mode of Administration, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Mode of Administration, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Mode of Administration, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- Northern Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Mode of Administration, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- Competitive Landscape
- Heat Map Analysis
- Company Profiles
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Boehringer Ingelheim GmbH
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Daiichi Sankyo, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Otsuka Pharmaceutical Company, Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- The Medicines Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- Section
- References
- Research Methodology
- About Us and Sales Contact
*Browse 31 market data tables and 33 figures on "Antiplatelet Drugs Market” - Global forecast to 2026”.
Share
Choose License Type
"How Can I Help You" ?
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Key Benefits
Custom Research Solution
Talk to our research consultant to design an exclusive report as per your research needs.
Customer Fulfilment
We aim to fulfil client's research demands with tailored research solutions.
Quick Turnaround Time Reports
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
360-degree Approach
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
Assured Quality
We strive to provide most accurate and reliable research findings in our research reports.